Integra LifeSciences Holdings Corporation

NasdaqGS:IART Voorraadrapport

Marktkapitalisatie: US$1.4b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Integra LifeSciences Holdings Inkomsten in het verleden

Verleden criteriumcontroles 1/6

Integra LifeSciences Holdings has been growing earnings at an average annual rate of 5.2%, while the Medical Equipment industry saw earnings growing at 11.8% annually. Revenues have been growing at an average rate of 1.6% per year. Integra LifeSciences Holdings's return on equity is 1.5%, and it has net margins of 1.5%.

Belangrijke informatie

5.2%

Groei van de winst

6.0%

Groei van de winst per aandeel

Medical Equipment Groei van de industrie8.9%
Inkomstengroei1.6%
Rendement op eigen vermogen1.5%
Nettomarge1.5%
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Why Investors Shouldn't Be Surprised By Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Low P/S

Sep 08
Why Investors Shouldn't Be Surprised By Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Low P/S

Is Integra LifeSciences Holdings (NASDAQ:IART) A Risky Investment?

Aug 21
Is Integra LifeSciences Holdings (NASDAQ:IART) A Risky Investment?

At US$29.14, Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Worth Looking At Closely?

Jul 01
At US$29.14, Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Worth Looking At Closely?

Integra LifeSciences Still Underperforming As Manufacturing Issues Linger

Jun 21

Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Intrinsic Value Is Potentially 40% Above Its Share Price

May 28
Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Intrinsic Value Is Potentially 40% Above Its Share Price

Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled

Feb 27
Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Feb 11
We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Jan 14
Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings

Dec 31
Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?

Dec 03
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?

Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?

Nov 06
Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?

Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns

Oct 24
Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns

Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Sep 22
Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?

Aug 15
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?

Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes

Jul 03
Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes

Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Jun 19
Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

May 05
Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

Apr 07
These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital

Mar 26
Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital

At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?

Mar 14
At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?

Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?

Feb 27
Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?

Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Feb 02
Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Jan 05
We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Here's What To Make Of Integra LifeSciences Holdings' (NASDAQ:IART) Decelerating Rates Of Return

Dec 21
Here's What To Make Of Integra LifeSciences Holdings' (NASDAQ:IART) Decelerating Rates Of Return

When Should You Buy Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Dec 08
When Should You Buy Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 42% Discount?

Oct 19
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 42% Discount?

Opbrengsten en kosten

Hoe Integra LifeSciences Holdings geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqGS:IART Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 241,5672461987
31 Mar 241,5304059581
31 Dec 231,5426859383
30 Sep 231,54310159383
30 Jun 231,54513160181
31 Mar 231,56217261584
31 Dec 221,55818161482
30 Sep 221,56517362581
30 Jun 221,56716661982
31 Mar 221,55915761479
31 Dec 211,54216963793
30 Sep 211,52621660474
30 Jun 211,50920659772
31 Mar 211,37817055568
31 Dec 201,37213459577
30 Sep 201,3785657377
30 Jun 201,387-358478
31 Mar 201,5122762381
31 Dec 191,5185068880
30 Sep 191,5066060874
30 Jun 191,49310161075
31 Mar 191,4758360876
31 Dec 181,4726169178
30 Sep 181,4588060775
30 Jun 181,3717057270
31 Mar 181,2876954666
31 Dec 171,1886551763
30 Sep 171,0754947560
30 Jun 171,0476646060
31 Mar 171,0146844659
31 Dec 169927543158
30 Sep 169856142657
30 Jun 16958941556
31 Mar 16919939553
31 Dec 15883737750
30 Sep 158541236047
30 Jun 158275334644
31 Mar 157824632542
31 Dec 147973633543
30 Sep 147983034547
30 Jun 14814-1035649
31 Mar 14855-1338051
31 Dec 136972230542

Kwaliteitswinsten: IART has a large one-off loss of $157.0M impacting its last 12 months of financial results to 30th June, 2024.

Groeiende winstmarge: IART's current net profit margins (1.5%) are lower than last year (8.5%).


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: IART's earnings have grown by 5.2% per year over the past 5 years.

Versnelling van de groei: IART's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Winst versus industrie: IART had negative earnings growth (-82%) over the past year, making it difficult to compare to the Medical Equipment industry average (7.9%).


Rendement op eigen vermogen

Hoge ROE: IART's Return on Equity (1.5%) is considered low.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden